Literature DB >> 10416521

Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease.

I Mezzaroma1, M Carlesimo, E Pinter, C Alario, G Sacco, D S Muratori, M L Bernardi, R Paganelli, F Aiuti.   

Abstract

OBJECTIVES: Evaluation of immunological reconstitution after 2 years of highly active antiretroviral therapy (HAART) in AIDS patients.
DESIGN: Previous data showed the effectiveness of HAART but conflicting evidence of immune reconstitution has been found in severely immunocompromised patients. Therefore, T-cell subsets and functions were analysed during 24 months of HAART in 21 AIDS patients (mean baseline CD4 cell count, 20 x 10(6)/l).
METHODS: Subjects were tested at baseline and after 4, 12 and 24 months of therapy for clinical symptoms and the following investigations were carried out: plasma HIV RNA, T-cell subsets and lymphoproliferative responses to mitogens (phytohaemagglutinin, anti-CD3), and recall antigens (Candida mannoprotein, tetanus toxoid and recombinant glycoprotein 160).
RESULTS: Increase in body weight, improvement of Karnofsky's score and reduction of opportunistic infections were observed. All patients showed an initial increase in the CD4 memory subset, whereas naive CD4 cells consistently increased only after 1 year. The magnitude of immune recovery was stronger in patients showing a significant reduction in viral load. However seven out of 21 patients who did not reach a sustained suppression of viral load showed also an increase in T-cell subsets. The majority of patients recovered lymphoproliferative responses to mitogens, whereas only four subjects showed a functional response to Candida mannoprotein. No patients showed a response to HIV recombinant glycoprotein 160 or tetanus toxoid.
CONCLUSIONS: The immune recovery observed is slower and not complete in severely immunocompromised patients. Our data suggest that HAART may be continued also in the absence of a significant HIV RNA decrease if alternative drugs are not available.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416521     DOI: 10.1097/00002030-199907090-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.

Authors:  D Scott-Algara; J P Aboulker; C Durier; E Badell; F Marcellin; M Prud'homme; C Jouanne; V Meiffredy; F Brun-Vezinet; G Pialoux; F Raffi
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

3.  Immune Reconstitution Strategies in HIV.

Authors:  Matthew R. Leibowitz; Ronald T. Mitsuyasu
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

4.  T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity.

Authors:  A Giovannetti; M Pierdominici; F Mazzetta; S Salemi; M Marziali; D Kuonen; F Iebba; E A Lusi; A Cossarizza; F Aiuti
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

5.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

6.  Latent reservoirs of HIV: obstacles to the eradication of virus.

Authors:  T W Chun; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

7.  Helping people with HIV/AIDS return to work: a randomized clinical trial.

Authors:  David J Martin; Robert A Chernoff; Michael Buitron; W Scott Comulada; Li-Jung Liang; F Lennie Wong
Journal:  Rehabil Psychol       Date:  2012-11-12

8.  Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure.

Authors:  M Peruzzi; C Azzari; L Galli; A Vierucci; M De Martino
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

Review 9.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy.

Authors:  Paola Paci; Rossella Carello; Massimo Bernaschi; Gianpiero D'Offizi; Filippo Castiglione
Journal:  BMC Infect Dis       Date:  2009-10-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.